Metropolitan Life Insurance Co. NY increased its stake in shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 324.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,872 shares of the specialty pharmaceutical company’s stock after buying an additional 2,195 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in ANI Pharmaceuticals were worth $129,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in the stock. Squarepoint Ops LLC acquired a new position in ANI Pharmaceuticals during the 4th quarter worth $656,000. D. E. Shaw & Co. Inc. grew its stake in ANI Pharmaceuticals by 13.7% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 5,794 shares of the specialty pharmaceutical company’s stock worth $261,000 after purchasing an additional 700 shares in the last quarter. Principal Financial Group Inc. grew its stake in ANI Pharmaceuticals by 0.8% during the 4th quarter. Principal Financial Group Inc. now owns 67,326 shares of the specialty pharmaceutical company’s stock worth $3,031,000 after purchasing an additional 529 shares in the last quarter. Geode Capital Management LLC grew its stake in ANI Pharmaceuticals by 3.0% during the 4th quarter. Geode Capital Management LLC now owns 97,459 shares of the specialty pharmaceutical company’s stock worth $4,387,000 after purchasing an additional 2,827 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in ANI Pharmaceuticals by 1.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 518,427 shares of the specialty pharmaceutical company’s stock worth $23,339,000 after purchasing an additional 6,546 shares in the last quarter. Hedge funds and other institutional investors own 59.75% of the company’s stock.
ANIP has been the subject of several analyst reports. TheStreet raised ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Tuesday, March 19th. Cantor Fitzgerald set a $74.00 target price on ANI Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, December 28th. Raymond James set a $73.00 target price on ANI Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, February 28th. BidaskClub raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, February 14th. Finally, ValuEngine raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, February 4th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. ANI Pharmaceuticals presently has an average rating of “Buy” and an average target price of $73.25.
NASDAQ:ANIP opened at $68.88 on Friday. The stock has a market cap of $816.30 million, a PE ratio of 14.94 and a beta of 2.42. ANI Pharmaceuticals Inc has a 1 year low of $36.92 and a 1 year high of $72.81. The company has a quick ratio of 0.68, a current ratio of 0.92 and a debt-to-equity ratio of 0.34.
ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Wednesday, February 27th. The specialty pharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.24 by $0.08. The business had revenue of $57.12 million during the quarter, compared to analysts’ expectations of $53.48 million. ANI Pharmaceuticals had a return on equity of 28.84% and a net margin of 7.69%. The business’s quarterly revenue was up 20.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.08 EPS. As a group, research analysts forecast that ANI Pharmaceuticals Inc will post 5.97 earnings per share for the current year.
In related news, SVP Robert W. Schrepfer sold 4,651 shares of the company’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $64.43, for a total value of $299,663.93. Following the completion of the sale, the senior vice president now directly owns 53,484 shares of the company’s stock, valued at approximately $3,445,974.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Arthur Przybyl sold 27,625 shares of the company’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $63.53, for a total value of $1,755,016.25. The disclosure for this sale can be found here. Corporate insiders own 33.10% of the company’s stock.
ANI Pharmaceuticals Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Further Reading: Asset Allocation, Balancing Your Investments
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.